Pharmaceutical manufacturers of Clobetasol propionate

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

Formed through the fusion of Farmabios, Novasep, and PharmaZell, Axplora stands out as a principal manufacturer of active pharmaceutical ingredients (APIs), ensuring the timely and scalable delivery of high-quality compounds. With a collective proficiency and a diverse production capacity spanning 9 industrial facilities, incorporating specialized technologies such as Hazardous Chemistry, Chromatography, ADCs, Steroids, Continuous Processes, Lipids, and HPAPIs, Axplora provides dependable and flexible solutions: CDMO services for small molecule APIs and biopharmaceuticals to both innovators and generic API Products. We, at Axplora, are committed to unifying Farmabios, Novasep, and PharmaZell, establishing ourselves as a top-tier API manufacturer dedicated to serving the foremost patient-focused pharmaceutical and biotechnology enterprises, ensuring the reliable and sustainable production of premium active ingredients in adherence to the highest industry standards. Axplora's mission is centered on empowering pharmaceutical companies to enhance the development of vital medications, fostering a faster, safer, and more dependable approach to benefit patients worldwide. Leveraging our combined expertise and manufacturing facilities spread across nine sites in Europe and India, along with a research and development center in the USA, Axplora is positioned to offer comprehensive CDMO solutions.

Symbiotec Pharmalab Pvt. Ltd is a prominent manufacturer of Active Pharmaceutical Ingredients (APIs) for Cortico Steroids and Sex Hormones, serving over 35 markets, including North America, Europe, Israel, and Japan. Established in 1995 in Central India, the company holds accreditations from US-FDA, EU-GMP, and WHO-GMP. It has received eighteen (18) Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs) from the European Directorate for the Quality of Medicines (EDQM) and has filed several Drug Master Files (DMFs) with EDQM and FDA. Symbiotec is dedicated to providing cGMP compliant material with comprehensive regulatory support, coupled with the advantage of lower production costs in Asia. The company offers Lyophilized Sterile and Micronized Steroids and Hormones with a particle size of up to 5 microns. For a complete range of products and further details, please visit their website.

Swati Spentose (SSPL) is a technology-driven manufacturing company specializing in the production and supply of both APIs & FDFs. Swati Spentose Pvt. Ltd. (SSPL) Unit 1 has been inspected by USFDA, certified by EU-GMP, approved by COFEPRIS in Mexico & MFDS in Korea, and WHO-GMP certified (www.spentose.com). They offer products such as Polysaccharide Block-Pentosan Polysulfate Sodium (PPS), Multipurpose Block-Lidocaine Base/HCl, Meloxicam, Melatonin, Granisetron Base/HCl, Prilocaine Base/HCL, Glycopyrrolate, Tamsulosin, Silodosin, Mirabegron. SSPL Unit-2 details are not provided.

Hovione brings over six decades of experience as a CDMO and serves as a specialized integrated provider delivering solutions for drug substance, drug product intermediate, and drug product. With four FDA examined facilities in the United States, China, Ireland, and Portugal, as well as research laboratories in Portugal and the United States, the company supplies pharmaceutical customers with services for the development and compliant production of innovative drugs, including highly potent compounds. Hovione delivers a comprehensive range of development services and manufacturing capabilities in particle engineering such as Spray Drying.

Founded as Xianju Pharmacy Plant in 1972, Xianju Pharmaceutical Co., Ltd. (stock code: 002332) practices the corporate philosophy of “ your health and happiness, my sincerity and service” and focuses on steroid hormones with the vision of “ Becoming the one of the Top 10 steroid hormone suppliers in the world and a business well-received among customers and employees.” It has a total capital stock of 989.204866 million yuan and more than 3600 employees. As a key high-tech enterprise of the National Torch Plan, the company ranked 67th among the top 100 in the Chinese pharmaceutical industry in 2020 with a provincial steroid medicine engineering technology research center in Zhejiang Province and a national post-doctoral center. As the only company holding fast to the business pattern integrating bulk pharmaceutical chemicals and preparations, the company specializes in the research, production and sale of bulk pharmaceutical chemicals and steroid preparations. In its product development, the company sticks to the four major fields of health care (gynecology, anesthesiology, respiratory medicine, and dermatology) to build mixes of products and services. The company has established long-term partnership with more than 20 domestic prestigious research institutes and universities including the Shanghai institute of Organic Chemistry, Chinese Academy of Sciences, Zhejiang University and China Pharmaceutical University to bring in senior researchers and gradually align with the new drug development in the world. The company has formed a technical framework that originates from overseas high-end research institutions, assimilates through the research institutions in Hangzhou and Xianju and Implements them with the base in Xianju. Under the company, there are 20 wholly-owned and holding subsidiaries such as time Xianju Pharmaceutical Co., Ltd. The company has three core manufacturing platforms, which are Xianju Yangfu bulk pharmaceutical chemicals production zone, Xianju Yangfu preparation production zone and Linhai Yangfu productions zone at home and two standard bulk pharmaceutical chemicals plants under the name of NewChem, its subsidiary in Italy. Xianju Pharma advocates the culture celebrating authenticity, win-win results and innovation and core values of honesty, hard work, openness, studiousness, responsibility and mutual benefit. Upholding the strategic objective of achieving win-win results with customers, enterprises, employees and communities, the company promotes the values that individuals’ value is reflected when they benefit their communities and companies. In its future development, the company will continue optimizing its business management, developing high-tech products and leverage on its large business size to achieve high-quality development and make contributions to the health care of mankind.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Anuh Pharma Ltd., a Bulk Drugs Manufacturing Company is part of the INR 8.5 bn SK Group of Companies, which employs 2000+ people across businesses such as Manufacturing of API's, Pharma Formulations, Distribution and Logistics. Established in 1960, Anuh Pharma Ltd. today is one of the largest manufacturers of Macrolides and Anti-TB products in India, besides being a major player in Anti-Bacterials, Anti-Malarial, and Corticosteroids.

Inabata France, a division of the Inabata Group, was established in 1990 to export chemical and medicinal products to Japan. It purchased Pharmasynthèse in 2006. Inabata-Pharmasynthèse provides an extensive range of services, including procurement, production, and innovation of raw materials for the pharmaceutical and beauty sectors. It delivers pharmaceutical and beauty components to Europe, Japan, and other regions worldwide. Its specialty lies in the manufacture of high-quality chemicals. Manufacturing is conducted at its versatile facility in St Pierre-Les-Elbeuf, France, ranging from pilot to commercial scales. The plant operates under GMP conditions.

Established in the year 1991, SM Biomed Sdn. Bhd. is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and Intermediates based out in Malaysia With our state-of-the-art manufacturing facility certified by USFDA, EDQM, EUGMP and NPRA (Malaysia), we are dedicated to improve the quality of life through developing and delivering innovative solutions and products at an affordable cost. With a legacy spanning more than three decades and pioneers for Macrolide based antibiotics, we work with customers globally with speed, efficiency and cost effective manufacturing capabilities. SM Biomed has grown as a market leader in Macrolides antibiotics and evolved into a knowledge driven company providing reliable pharmaceutical services including developing and manufacturing APIs and Intermediates. From pipeline to production, we make innovative, quality driven and customised products more accessible. We are a quality driven and R&D focused API manufacturing company with a diverse product portfolio catering various therapeutic segments.

Symbiotica produces active pharmaceutical ingredients at their cGMP Facility certified as ICHQ7, PIC/S GMP, successfully examined by the USFDA, COFEPRIS & PMDA. Regularly reviewed by clients including MNC's. Facilities comprise of Dedicated Steroidal & Specialized Non-steroidal blocks. A new Sterile-Steroidal facility is being established at a new location. We possess 11 CEP's & 8 USDMF's

Vamsi Labs, founded in 1991, is a prominent Indian producer of active pharmaceutical ingredients (API). It specializes in anti-asthmatic, anti-migraine, and anti-psychotic APIs, serving both domestic and international markets with 50% sales contribution from the latter. Sales of anti-asthma products make up 60% of the total sales. Vamsi upholds stringent corporate governance, transparency, professionalism, and environmental conservation standards. The company is approved by USFDA and holds certifications for ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. It also features a DSIR-certified R&D Lab, allowing Vamsi to continue innovating to meet the evolving requirements of the pharmaceutical industry. Vamsi is positioned for global expansion while maintaining its dedication to excellence and sustainability.

Coral Drugs operates as a fully integrated and autonomous research-oriented Global Pharmaceutical Company specializing in the production of a wide variety of premium APIs. The company's headquarters are located in the capital city of New Delhi, India. Its API focus encompasses multiple therapeutic areas and its facilities have obtained approvals from the USFDA, EUGMP and regulatory bodies in India. At Coral, there is a strong emphasis on upholding superior quality standards across products, services, and quality systems. The company's dedication to its customers is evident in its capacity to fulfill their tailored requirements and provide comprehensive product documentation.

Henan Lihua Pharmaceutical Co., Ltd., was founded in 1994, used to employ Diosgenin as starting material to develop various corticosteroid APIs, which was very rich in China. In recent years, the company strived to make transformation since the lack of Diosgenin and rising costs in China and succeeded finally. Now the company takes phytosterol as starting material to manufacture various of corticosteroid APIs and related core intermediates, with advanced fermentation and chemical synthesis technologies. Products quality meet the following pharmacopeia specifications: Ph.Eur., USP, JP, IP and Ch.P. and products are sold all over the world

R.N. Laboratories originated under the guidance of Mr Rohit Garg (Managing Director) and Mr Nitin Garg (technical director) in 1996. It stands as the leading global manufacturer of chlorhexidine gluconate 20% sol and its compositions, shipping to over 100 nations. Our goal is to produce reliable products of continuous and guaranteed quality, Safety, Efficacy, Purity, and provide alternative, generic, Active pharmaceutical ingredients; and finished dosage forms at a reasonable price.